<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468648</url>
  </required_header>
  <id_info>
    <org_study_id>150143</org_study_id>
    <secondary_id>15-DK-0143</secondary_id>
    <nct_id>NCT02468648</nct_id>
  </id_info>
  <brief_title>Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816</brief_title>
  <official_title>Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Chronic hepatitis C is a serious liver disease. Current treatments have side effects. New&#xD;
      drugs have been developed, but they work better in some people than others. Researchers want&#xD;
      to learn why.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To learn why new hepatitis C drugs sometimes do not work. Also, to learn if these drugs are&#xD;
      safe and how well they work in people with different virus strains.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Adults age 18 and older who are infected with hepatitis C virus genotypes 1-4 and who have&#xD;
      either never been treated or treated previously with an interferon regimen (with or without&#xD;
      ribavirin) that failed to clear the virus.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with medical history and physical exam. They will have&#xD;
           blood and urine tests and complete questionnaires.&#xD;
&#xD;
        -  Participants will have a Fibroscan, an ultrasound that measures liver stiffness and&#xD;
           other liver scans. They will have an electrocardiogram.&#xD;
&#xD;
        -  Eligible participants will have a liver biopsy.&#xD;
&#xD;
        -  Participants will be admitted to the Clinical Center. They will have a physical exam and&#xD;
           blood tests, and complete questionnaires.&#xD;
&#xD;
        -  They will take the first study drug dose as a tablet taken once daily.&#xD;
&#xD;
        -  Participants will take the drug at home for 12 weeks.&#xD;
&#xD;
        -  Participants will have 6 study visits. They will have blood and vital signs taken, and&#xD;
           complete questionnaires.&#xD;
&#xD;
        -  At week 4, participants will have another liver biopsy.&#xD;
&#xD;
        -  After their last drug dose, participants will have 5 follow-up visits. They will have&#xD;
           blood and vital signs taken, and complete questionnaires. They will discuss their&#xD;
           medications and side effects. They may have another Fibroscan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 140 patients with chronic hepatitis C, genotypes 1-4, who were never treated or&#xD;
      previously treated but failed a course of therapy with any interferon and ribavirin&#xD;
      combination regimen will be eligible to be enrolled into this pilot study to evaluate the&#xD;
      combination of sofosbuvir and GS-5816 as a fixed dose tablet to improve response to antiviral&#xD;
      therapy. To enrich the study population with subjects with a greater likelihood of&#xD;
      virological relapse after stopping therapy, we plan to enroll a minimum of 60%&#xD;
      treatment-experienced subjects and 50% with cirrhosis. These two drugs inhibit key enzymes&#xD;
      that are necessary for viral replication. Sofosbuvir, an NS5B polymerase inhibitor is already&#xD;
      approved for use in combination with interferon and ribavirin for the treatment of HCV&#xD;
      genotype 1 infection. GS-5816 is an NS5A replication complex inhibitor with potent activity&#xD;
      against most strains of hepatitis C virus. Combining these two agents into a single pill&#xD;
      should improve patient compliance and improve tolerability because interferon and ribavirin&#xD;
      will not be part of the regimen. After medical evaluation and liver biopsy, patients will&#xD;
      receive combination therapy with sofosbuvir and GS-5816 one pill a day for 12 weeks. The&#xD;
      baseline liver biopsy is necessary to assess the amount of liver damage caused by the HCV and&#xD;
      to measure expression of genes associated with clearance of HCV. Blood samples will be&#xD;
      collected to monitor safety and response to therapy and for research purposes. HCV RNA levels&#xD;
      will be monitored frequently for the initial 4 weeks and then at monthly intervals for the&#xD;
      remaining 8 weeks of antiviral therapy. All subjects will undergo a second liver biopsy, 4&#xD;
      weeks after starting therapy. The second biopsy is being performed for research purposes so&#xD;
      investigators can determine specifically which liver genes are associated with failure of&#xD;
      therapy (and response to therapy). Subjects who refuse the second liver biopsy will continue&#xD;
      to receive SOF/GS-5816 treatment for the planned 12 week duration Patients in whom serum HCV&#xD;
      RNA is greater than or equal to lower limit of quantification (LLOQ) after 2 consecutive HCV&#xD;
      RNA &lt; LLOQ or who have a confirmed &gt; 1 log10 increase from nadir will discontinue therapy&#xD;
      (because continuing therapy is considered futile i.e. it is unlikely to work). The major&#xD;
      endpoints will be changes in interferon stimulated gene and protein expression in the liver&#xD;
      and changes in HCV RNA levels in liver and serum between baseline and 4 weeks and rates of&#xD;
      sustained virologic response at post-treatment week 12. Secondary endpoints will be safety&#xD;
      and sustained virologic response at post-treatment week 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 9, 2015</start_date>
  <completion_date type="Actual">September 14, 2018</completion_date>
  <primary_completion_date type="Actual">September 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Virologic Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absence of detectable virus 12 weeks after completion of antiviral therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Sustained Virologic Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Absence of detectable virus 24 weeks after completion of antiviral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Combination of sofosbuvir and GS-5816</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection</description>
    <arm_group_label>Combination of sofosbuvir and GS-5816</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5816</intervention_name>
    <description>An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
    <arm_group_label>Combination of sofosbuvir and GS-5816</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for participation&#xD;
        in this study.&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Male or female, age greater than or equal to18 years.&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 18 kg/m^2.&#xD;
&#xD;
          -  HCV RNA greater than or equal to10^4 IU/mL at Screening&#xD;
&#xD;
          -  HCV genotypes 1a, 1b, 2, 3 or 4 at screening&#xD;
&#xD;
          -  Confirmation of chronic HCV infection documented by either:&#xD;
&#xD;
               -  A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping&#xD;
                  test at least 6 months prior to the Baseline/Day 1 visit, or&#xD;
&#xD;
               -  A liver biopsy performed within 12 weeks prior to the Baseline/Day 1 visit with&#xD;
                  evidence of chronic HCV infection. A prior biopsy would be acceptable if&#xD;
                  performed with 12 weeks AND liver tissue stored in RNALater was available.&#xD;
&#xD;
          -  Screening ECG without clinically significant abnormalities.&#xD;
&#xD;
          -  Subjects must have the following laboratory parameters at screening:&#xD;
&#xD;
               -  ALT less than or equal to 10 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  AST less than or equal to 10 times ULN&#xD;
&#xD;
               -  Direct bilirubin less than or equal to 1.5 ULN&#xD;
&#xD;
               -  Platelets &gt; 70,000&#xD;
&#xD;
               -  HbA1c less than or equal to8.5%&#xD;
&#xD;
               -  eGFR greater than or equal to 60 mL /min, as calculated by the CKD-EPI equation.&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 10g/dL.&#xD;
&#xD;
               -  Albumin greater than or equal to 3g/dL&#xD;
&#xD;
               -  INR less than or equal to 1.5 x ULN unless subject has known hemophilia or is&#xD;
                  stable on an anticoagulant regimen affecting INR.&#xD;
&#xD;
          -  A female subject is eligible to enter the study if it is confirmed that she is:&#xD;
&#xD;
               -  Not pregnant or nursing&#xD;
&#xD;
               -  Of non-childbearing potential (i.e., women who have had a hysterectomy, have both&#xD;
                  ovaries removed or medically documented ovarian failure, or are postmenopausal&#xD;
                  women &gt; 50 years of age with cessation (for greater than or equal to 12 months)&#xD;
                  of previously occurring menses),&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Of childbearing potential (i.e., women who have not had a hysterectomy, have not had&#xD;
             both ovaries removed, and have not had medically documented ovarian failure). Women&#xD;
             less than or equal to 50 years of age with amenorrhea will be considered to be of&#xD;
             childbearing potential. These women must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on the Baseline/Day 1 visit prior to&#xD;
             randomization. They must also agree to one of the following from 3 weeks prior to&#xD;
             Baseline/Day 1 until 90 days after last dose of study drug:&#xD;
&#xD;
               -  Complete abstinence from intercourse. Periodic abstinence from intercourse (e.g.,&#xD;
                  calendar, ovulation, symptothermal, post-ovulation methods) is not permitted.&#xD;
&#xD;
               -  Consistent and correct use of 1 of the following methods of birth control listed&#xD;
                  below in addition to a male partner who correctly uses a condom from the date of&#xD;
                  Screening until 90 days after last dose of study drug:&#xD;
&#xD;
                    -  intrauterine device (IUD) with a failure rate of &lt; 1% per year&#xD;
&#xD;
                    -  female barrier method: cervical cap or diaphragm with spermicidal agent&#xD;
&#xD;
                    -  tubal sterilization&#xD;
&#xD;
                    -  vasectomy in male partner&#xD;
&#xD;
                    -  hormone-containing contraceptive:&#xD;
&#xD;
                         -  implants of levonorgestrel&#xD;
&#xD;
                         -  injectable progesterone&#xD;
&#xD;
                         -  oral contraceptives (either combined or progesterone only)&#xD;
&#xD;
                         -  contraceptive vaginal ring&#xD;
&#xD;
                         -  transdermal contraceptive patch&#xD;
&#xD;
                              -  All male study participants must agree to consistently and&#xD;
                                 correctly use a condom, while their female partner agrees to use 1&#xD;
                                 of the methods of birth control listed above, from the date of&#xD;
                                 Screening until 90 days after last dose of study drug.&#xD;
&#xD;
                              -  Male subjects must agree to refrain from sperm donation from 90&#xD;
                                 days after their last dose of study drug.&#xD;
&#xD;
                              -  Subject must be of generally good health, with the exception of&#xD;
                                 chronic HCV infection, as determined by the Investigator.&#xD;
&#xD;
                              -  Subject must be able to comply with the dosing instructions for&#xD;
                                 study drug administration and able to complete the study schedule&#xD;
                                 of assessments, including all required post treatment visits.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria will not to be enrolled in this&#xD;
        study.&#xD;
&#xD;
          -  Current or prior history of any of the following:&#xD;
&#xD;
               -  Clinically-significant illness (other than HCV) or any other major medical&#xD;
                  disorder that may interfere with subject treatment, assessment or compliance with&#xD;
                  the protocol; subjects currently under evaluation for a potentially&#xD;
                  clinically-significant illness (other than HCV) are also excluded.&#xD;
&#xD;
               -  Gastrointestinal disorder or post-operative condition that could interfere with&#xD;
                  the absorption of the study drug.&#xD;
&#xD;
               -  Difficulty with blood collection and/or poor venous access for the purposes of&#xD;
                  phlebotomy.&#xD;
&#xD;
               -  Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal&#xD;
                  hemorrhage).&#xD;
&#xD;
               -  Solid organ transplantation.&#xD;
&#xD;
               -  Significant pulmonary disease, significant cardiac disease or porphyria.&#xD;
&#xD;
               -  Psychiatric hospitalization, suicide attempt, and/or a period of disability as a&#xD;
                  result of their psychiatric illness within the last 5 years. Subjects with&#xD;
                  psychiatric illness (without the prior mentioned conditions) that is&#xD;
                  well-controlled on a stable treatment regimen for at least 12 months prior to&#xD;
                  randomization or has not required medication in the last 12 months may be&#xD;
                  included.&#xD;
&#xD;
               -  Malignancy within 5 years prior to screening, with the exception of specific&#xD;
                  cancers that are entirely cured by surgical resection (basal cell skin cancer,&#xD;
                  etc). Subjects under evaluation for possible malignancy are not eligible.&#xD;
&#xD;
               -  Significant drug allergy (such as anaphylaxis or hepatotoxicity).&#xD;
&#xD;
          -  Any prior treatment with a direct acting antiviral agent (protease inhibitors, NS5A&#xD;
             inhibitors and NS5B polymerase inhibitors/non-nucleoside polymerase inhibitors.)&#xD;
&#xD;
          -  Pregnant or nursing female or male with pregnant female partner.&#xD;
&#xD;
          -  Chronic liver disease of a non HCV etiology (e.g., hemochromatosis, Wilson s disease,&#xD;
             alfa 1 antitrypsin deficiency, cholangitis).&#xD;
&#xD;
          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Clinically-relevant drug abuse within 12 months of screening. A positive drug screen&#xD;
             will exclude subjects unless it can be explained by a prescribed medication; the&#xD;
             diagnosis and prescription must be approved by the investigator.&#xD;
&#xD;
          -  Use of any prohibited concomitant medications as described within 21 days of the&#xD;
             Baseline/Day 1 visit; this washout period does not apply to PPIs, which can be taken&#xD;
             up to 7 days before baseline Day 1.&#xD;
&#xD;
          -  Use of antiviral medications within the last 30 days.&#xD;
&#xD;
          -  Chronic use of systemically administered immunosuppressive agents (e.g., prednisone&#xD;
             equivalent &gt; 10 mg/day).&#xD;
&#xD;
          -  Known hypersensitivity to GS-5816, SOF, or formulation excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc G Ghany, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-DK-0143.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>September 14, 2018</verification_date>
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <results_first_submitted>February 26, 2020</results_first_submitted>
  <results_first_submitted_qc>March 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2020</results_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Therapy</keyword>
  <keyword>Liver Biopsy</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02468648/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02468648/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination of Sofosbuvir and GS-5816</title>
          <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination of Sofosbuvir and GS-5816</title>
          <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Virologic Response</title>
        <description>Absence of detectable virus 12 weeks after completion of antiviral therapy</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Sofosbuvir and GS-5816</title>
            <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virologic Response</title>
          <description>Absence of detectable virus 12 weeks after completion of antiviral therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Sofosbuvir and GS-5816</title>
            <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Sustained Virologic Response</title>
        <description>Absence of detectable virus 24 weeks after completion of antiviral therapy</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Sofosbuvir and GS-5816</title>
            <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Sustained Virologic Response</title>
          <description>Absence of detectable virus 24 weeks after completion of antiviral therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination of Sofosbuvir and GS-5816</title>
            <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combination of Sofosbuvir and GS-5816</title>
          <description>Combination of sofosbuvir and GS-5816 agent into a single pill will be used.&#xD;
Sofosbuvir: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection&#xD;
GS-5816: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain after a radiological biopsy and direct cannulation of the portal vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="16" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="86" subjects_affected="26" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="38" subjects_affected="20" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="204" subjects_affected="44" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="32" subjects_affected="19" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="38" subjects_affected="21" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="142" subjects_affected="36" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="171" subjects_affected="47" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Trouble sleeping</sub_title>
                <counts group_id="E1" events="159" subjects_affected="36" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="76" subjects_affected="30" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <counts group_id="E1" events="85" subjects_affected="35" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Iching</sub_title>
                <counts group_id="E1" events="84" subjects_affected="31" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Ghany, MD, MHSc</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-402-5115</phone>
      <email>marcg@intra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

